Children's Hospital Colorado, University of Colorado School of Medicine, Section of Allergy and Immunology, Aurora, Colorado.
Ann Allergy Asthma Immunol. 2018 May;120(5):476-481.e3. doi: 10.1016/j.anai.2018.03.011. Epub 2018 Mar 16.
To review the evidence of the risk of environmental exposure to peanut to a peanut allergic individual.
A narrative review was performed using a PubMed search of relevant articles involving peanut environmental distribution, environmental peanut abatement, and public policy regarding peanut restriction.
Data from 4 studies have shown that peanut butter vapors and smeared peanut butter on skin do not cause systemic reactions, that peanut can be abated from hands and surfaces using appropriate cleaning agents, and that shelled peanut dust does not become airborne. Studies have recently confirmed dose of 1.5 mg of peanut protein would be generally tolerated by approximately 95% of the peanut-allergic population based on objective symptoms in challenge-based studies, affirming earlier research. Restrictive policies that focus on bans (or restricted presence in certain areas) of peanuts or peanut-containing products in environments such as schools or on commercial aircraft are not backed by evidence that such measures work, which may raise an uncomfortable clash between accommodations that lack any medical evidence of necessity and a desire to provide measures that comfort our patients.
There is little risk posed from non-oral exposure to peanut in the environment, from casual contact, proximity, or inhalation. If 5% of the population may tolerate a threshold of approximately 1.5 mg of peanut protein, this may help liberate behavior and situational-decision making regarding the necessity of certain avoidances and restrictions. Continued work is needed to dispel myths about the mechanisms of how peanut may induce an allergic reaction.
综述环境中花生暴露对花生过敏个体的风险证据。
采用 PubMed 检索相关文章,对涉及花生环境分布、环境中花生消减和关于花生限制的公共政策的文章进行叙述性综述。
4 项研究的数据表明,花生酱蒸气和涂抹在皮肤上的花生酱不会引起全身反应,可以使用适当的清洁剂从手上和表面清除花生,去壳的花生粉尘不会飞扬。最近的研究证实,根据基于挑战的研究中客观症状,约 95%的花生过敏人群可耐受 1.5 毫克的花生蛋白剂量,这证实了早期的研究。限制政策侧重于在学校或商业飞机等环境中禁止(或限制某些区域存在)花生或含花生产品,但这些措施并没有得到证据支持,这可能会在缺乏任何必要医疗证据的适应措施和为患者提供舒适措施之间引发不适的冲突。
环境中非口服暴露于花生、偶然接触、接近或吸入花生的风险很小。如果 5%的人口可能耐受约 1.5 毫克的花生蛋白阈值,这可能有助于解放关于某些回避和限制的行为和情境决策。需要继续努力消除关于花生如何引起过敏反应的机制的误解。